BioCurex, Inc.(fka BOCX)

[Gold Seeker]

The bocx stated: "In any case, who cares? RECAF's market for monitoring cancer is very, very large (perhaps larger than PSA's for screening) and according to you, it would be the first application to get FDA approval."

The number of cancers present at any one time for monitoring is about 10 million and lets assume just screening the population over 50 with RECAF and compare numbers.

For screening everyone over 50 once a year, 112 million RECAF tests would be giver per year.

For monitoring and lets even assume a RECAF test was given once a year, that would only be 10 million tests compared to 112 million possible for screening. There is no way that monitoring remotely compares to the revenue from screening even if RECAF was approved to monitor every cancer out there.